Skip to main content

Table 2 Culture conversion by culture method and treatment arm at month-2, 4 and 6

From: Predictors of delayed culture conversion among Ugandan patients

Month Culture Overall Treatment Arm  
CR SR1 SR2 p-valueb
Converted, n/N, % Converted, n/N, % Converted, n/N,% Converted, n/N, %  
Month-2 LJ 51/91 (56.0) 17/32 (53.1) 14/27 (51.9) 20/32 (62.5) 0.697
MGIT 46/95 (48.4) 18/33 (54.6) 13/31 (41.9) 15/31 (48.4) 0.601
% difference 7.6 −1.5 10 14.1  
p-valuea 0.0707 1.0000 0.1250 0.2891  
Both LJ and MGIT 45/100 (45.0) 17/34 (50.0) 13/32 (40.6) 15/34 (44.1) 0.721
Month-4 LJ 88/89 (98.9) 31/31 (100.0) 28/29 (96.6) 29/29 (100.0) 0.652
MGIT 76/86 (88.4) 29/32 (90.6) 24/27 (88.9) 23/27 (85.2) 0.913
% difference 10.5 9.4 7.7 14.8  
p-valuea 0.0391 0.5000 0.6250 0.2500  
Both LJ and MGIT 82/94 (87.2) 31/34 (91.2) 25/30 (83.3) 26/30 (86.7) 0.685
Month-6 LJ 87/87 (100.0) 33/33 (100.0) 26/26 (100.0) 28/28 (100.0) NA
MGIT 78/78 (100.0) 29/29 (100.0) 26/26 (100.0) 23/23 (100.0) NA
% difference 0.0 0.0 0.0 0.0  
p-valuea 1.0000 1.0000 1.0000 1.0000  
Both LJ and MGIT 88/88 (100.0) 34/34 (100.0) 26/26 (100.0) 28/28 (100.0) NA
  1. aExact McNemar p-value
  2. bFishers’ exact p-value
  3. Converted culture converted, CR control regimen (10 mg/kg rifampicin), SR1 study regimen1 (15 mg/kg rifampicin), SR2 study regimen2 (20 mg/kg rifampicin), LJ Löwenstein-Jensen, MGIT mycobacterium growth indicator tube